ALK’s EURneffy secures MHRA approval for anaphylaxis treatment

​ALK has received marketing authorisation from the MHRA for EURneffy 1mg, a needle-free adrenaline treatment for children with anaphylaxis.

The post ALK’s EURneffy secures MHRA approval for anaphylaxis treatment appeared first on Hospital Management.

 

Back to the Featured Stories

Featured Stories

FDA approves Bayer’s Ambelvist contrast agent
Lilly reports Phase III BRUIN CLL-322 trial results for Jaypirca combo
FDA clears MSD’s Keytruda combo plus Welireg for ccRCC treatment
Fleming Initiative and Cepheid begin TRACE-CPE study on rapid CPE testing
First patient treated in Airiver Medical’s RESTORE-2 trial for CRS

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.

Contact Us